Каприн А.Д., Старинский В.В., Шахзадова А.О. Злокачественные новообразования в России в 2019 г. (заболеваемость и смертность). М.: МНИОИ имени П.А. Герцена – филиал ФГБУ «НМИЦ радиологии»; 2020. 252 с.
Tannock I.F., Osoba D., Stockler M.R., Ernst D.S., Neville A.J., Moore M.J. et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14(6):1756–1764. https://doi.org/10.1200/jco.1996.14.6.1756..
DOI: 10.1200/jco.1996.14.6.1756
Sweeney C.J., Monaco F.J., Jung S.H., Wasielewski M.J., Picus J., Ansari R.H. et al. A phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer. Ann Oncol. 2002;13(3):435–440. https://doi.org/10.1093/annonc/mdf029..
DOI: 10.1093/annonc/mdf029
Nakabayashi M., Ling J., Xie W., Regan M.M., Oh W.K. Response to vinorelbine with or without estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancer. Cancer J. 2007;13(2):125–129. https://doi.org/10.1097/PPO.0b013e3180465940..
DOI: 10.1097/PPO.0b013e3180465940
Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–1512. https://doi.org/10.1056/NEJMoa040720..
DOI: 10.1056/NEJMoa040720
Petrylak D.P., Tangen C.M., Hussain M.H., Lara P.N. Jr, Jones J.A., Taplin M.E. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–1520. https://doi.org/10.1056/NEJMoa041318..
DOI: 10.1056/NEJMoa041318
Ryan C.J., Smith M.R., de Bono J.S., Molina A., Logothetis C.J., de Souza P. et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138–148. https://doi.org/10.1056/NEJMoa1209096..
DOI: 10.1056/NEJMoa1209096
Scher H.I., Fizazi K., Saad F., Taplin M.E., Sternberg C.N., Miller K. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–197. https://doi.org/10.1056/NEJMoa1207506..
DOI: 10.1056/NEJMoa1207506
Fizazi K., Scher H.I., Molina A., Logothetis C.J., Chi K.N., Jones R.J. et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13(10):983–992. https://doi.org/10.1016/S1470-2045(12)70379-0..
DOI: 10.1016/S1470-2045(12)70379-0
Kyriakopoulos C.E., Chen Y.H., Carducci M.A., Liu G., Jarrard D.F., Hahn N.M. et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol. 2018;36(11):1080–1087. https://doi.org/10.1200/JCO.2017.75.3657..
DOI: 10.1200/JCO.2017.75.3657
James N.D., Sydes M.R., Clarke N.W., Mason M.D., Dearnaley D.P., Spears M.R. et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163–1177. https://doi.org/10.1016/S0140-6736(15)01037-5..
DOI: 10.1016/S0140-6736(15)01037-5
Gravis G., Fizazi K., Joly F., Oudard S., Priou F., Esterni B. et al. Androgendeprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(2):149–158. https://doi.org/10.1016/S1470-2045(12)70560-0..
DOI: 10.1016/S1470-2045(12)70560-0
Gravis G., Boher J.M., Joly F., Soulié M., Albiges L., Priou F. et al. Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial. Eur Urol. 2016;70(2):256–262. https://doi.org/10.1016/j.eururo.2015.11.005..
DOI: 10.1016/j.eururo.2015.11.005
Fizazi K., Tran N., Fein L., Matsubara N., Rodriguez-Antolin A., Alekseev B.Y. et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20(5):686–700. https://doi.org/10.1016/S1470-2045(19)30082-8..
DOI: 10.1016/S1470-2045(19)30082-8
James N.D., de Bono J.S., Spears M.R., Clarke N.W., Mason M.D., Dearnaley D.P. et al. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N Engl J Med. 2017;377(4):338–351. https://doi.org/10.1056/NEJMoa1702900..
DOI: 10.1056/NEJMoa1702900
Beer T.M., Armstrong A.J., Rathkopf D.E., Loriot Y., Sternberg C.N., Higano C.S. et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424–433. https://doi.org/10.1056/NEJMoa1405095..
DOI: 10.1056/NEJMoa1405095
Beer T.M., Armstrong A.J., Rathkopf D.E., Loriot Y., Sternberg C.N., Higano C.S. et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424–433. https://doi.org/10.1056/NEJMoa1405095..
DOI: 10.1056/NEJMoa1405095
Scher H.I., Fizazi K., Saad F., Taplin M.E., Sternberg C.N., Miller K. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–1197. https://doi.org/10.1056/NEJMoa1207506..
DOI: 10.1056/NEJMoa1207506
Hussain M., Fizazi K., Saad F., Rathenborg P., Shore N., Ferreira U. et al. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2018;378(26):2465–2474. https://doi.org/10.1056/NEJMoa1800536..
DOI: 10.1056/NEJMoa1800536
Armstrong A.J., Szmulewitz R.Z., Petrylak D.P., Holzbeierlein J., Villers A., Azad A. et al. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2019;37(32):2974–2986. https://doi.org/10.1200/JCO.19.00799..
DOI: 10.1200/JCO.19.00799
Armstrong A.J., Iguchi T., Azad A.A., Szmulewitz R.Z., Holzbeierlein J., Villers A. et al. LBA25 – Final overall survival (OS) analysis from ARCHES: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC). Ann Oncol. 2021;32(5 Suppl.): S1300–S1301. https://doi.org/10.1016/j.annonc.2021.08.2101..
DOI: 10.1016/j.annonc.2021.08.2101
Davis I.D., Martin A.J., Stockler M.R., Begbie S., Chi K.N., Chowdhury S. et al. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. N Engl J Med. 2019;381(2):121–131. https://doi.org/10.1056/NEJMoa1903835..
DOI: 10.1056/NEJMoa1903835
Носов Д.А., Волкова М.И., Гладков О.А., Карабина Е.В., Крылов В.В., Матвеев В.Б. и др. Практические рекомендации по лекарственному лечению рака предстательной железы. Злокачественные опухоли. 2020;10(3s2–1):556–572. https://doi.org/10.18027/2224-5057-2020- 10-3s2-33..
DOI: 10.18027/2224-5057-2020- 10-3s2-33
Носов Д.А., Волкова М.И., Гладков О.А., Карабина Е.В., Крылов В.В., Матвеев В.Б. и др. Практические рекомендации по лекарственному лечению рака предстательной железы. Злокачественные опухоли. 2020;10(3s2–1):556–572. https://doi.org/10.18027/2224-5057-2020- 10-3s2-33..
DOI: 10.18027/2224-5057-2020-10-3s2-33
Fizazi K., Scher H.I., Miller K., Basch E., Sternberg C.N., Cella D. et al. Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. Lancet Oncol. 2014;15(10):1147–1156. https://doi.org/10.1016/S1470-2045(14)70303-1..
DOI: 10.1016/S1470-2045(14)70303-1